Tobin, David

From: Trials <Trials@USPTO.GOV>
Sent: Tuesday, November 18, 2025 1:52 PM
To: Tobin, David; Trials
Cc: James Murphy; Corey Casey; Sitzman, Mike; Best, Tim; Raymond.Miller; Endejann, Nicole
Subject: RE: IPR2025-00464, -465, -466: Stipulation and Request for Authorization re Due Dates 1-3

You don't often get email from trials@uspto.gov. Learn why this is important

[External Email]

Counsel,

The Board authorizes the parties' proposed schedule change as reflected in the email below. The parties should file a notice of stipulation reflecting those changes in each of the related cases.

Regards,

Andrew Kellogg,
Deputy Chief Clerk, Trials
Patent Trial and Appeal Board
USPTO
andrew.kellogg@uspto.gov
(571) 272-5366



From: Tobin, David <dtobin@mwe.com>
Sent: Friday, November 7, 2025 2:42 PM
To: Trials <Trials@USPTO.GOV>
Cc: James Murphy <jpmurphy@polsinelli.com>; Corey Casey <CCasey@Polsinelli.com>; Sitzman, Mike <msitzman@mwe.com>; Best, Tim <tbest@mwe.com>; Raymond.Miller <Raymond.Miller@us.dlapiper.com>; Endejann, Nicole <Nicole.Endejann@us.dlapiper.com>; Tobin, David <dtobin@mwe.com>
Subject: IPR2025-00464, -465, -466: Stipulation and Request for Authorization re Due Dates 1-3

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Dear Board,

I write jointly on behalf of Patent Owner and Petitioner regarding modifying the schedule in IPR2025-00464, -00465, and -00466. Due to unavailability of Petitioner's expert declarant (Dr. Donovan) and Petitioner's counsel, Patent Owner is unable to take the deposition of Dr. Donovan before the currently

NEURELIS, INC., EX2081, Page 1
PADAGIS US LLC v. NEURELIS, INC.
IPR2025-00464, U.S. PATENT 8,895,546

scheduled Due Date 1. Accordingly, Petitioner and Patent Owner jointly stipulate to move Due Dates 1 – 3 as follows:

Event	Current Deadline	Proposed Deadline
Due Date 1	December 9, 2025	January 5, 2026
Due Date 2	March 3, 2026	March 24, 2026
Due Date 3	April 14, 2026	May 5, 2026
Due Date 4	May 5, 2026	(Unchanged)
Due Date 5	May 26, 2026	(Unchanged)
Due Date 6	June 2, 2026	(Unchanged)
Due Date 7	June 9, 2026	(Unchanged)
Due Date 8	June 16, 2026	(Unchanged)

The three cases (IPR2025-00464, -00465, and -00466) are currently on the same schedule, and the parties jointly stipulate that the above deadlines will apply to all three cases.

Patent Owner is still analyzing the three petitions and has not determined whether it will seek a motion to amend on Due Date 1 in any of the three cases. So that the three cases can remain on the same schedule, the parties jointly request that the Board authorize the parties to move Due Date 2 in its entirety (i.e., Petitioner's reply to POR and Petitioner's opposition to MTA) and to move Due Date 3 in its entirety (i.e., PO sur-reply, PO's reply to Opposition to MTA, and PO's RMTA), each according to the above schedule.

Please let us know if the Board authorizes the schedule changes and, if so, Petitioner can file a notice of stipulation with the revised schedule.

If a conference call would be helpful, Petitioner and Patent Owner can make themselves available at a time that works best for the Board.

Sincerely,

David Tobin
Counsel for Patent Owner

David Tobin
Partner

T: +1 214 210 2793 | **F:** +1 972 232 3098
dtobin@mwe.com | LinkedIn

McDermott Will & Schulte LLP | mwe.com
2801 North Harwood Street, Suite 2600, Dallas, TX 75201



****
This message is a PRIVATE communication. This message and all attachments are a private communication sent by a

law firm and may be confidential or protected by privilege. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of the information contained in or attached to this message is strictly prohibited. Please notify the sender of the delivery error by replying to this message, and then delete it from your system. Our Privacy Policy explains how we may use your personal information. Thank you.
****

Please visit http://www.mwe.com/ for more information about our Firm.